Hepatitis Clinical Trials

UC San Diego Health System is currently conducting multiple clinical trials related to hepatitis. You can read descriptions about our hepatitis clinical trials below. Viral hepatitis clinical trials are managed by the UC San Diego Antiviral Research Center (AVRC). Detailed data on clinical trials and all reported results are available to the general public at www.clinicaltrials.gov.

GS-US-243-0102: A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Treatment Naive Subjects with Chronic Heptitis C Virus Infection.

Sponsor:  Gilead
Indication: Hepatitis C
Criteria: No previous treatment; requires overnight stays at the CTRI
Phase: 1
Drug: GS-9620 oral small-molecule TLR7-agonist

GS-US-283-0102: A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Heptitis B Virus Infection.

Sponsor:  Gilead
Indication: Hepatitis B
Criteria: Requires overnight stays at the CTRI
Phase: 1
Drug: GS-9620 oral small-molecule TLR7-agonist

GS-US-283-0106: A Double-Blind, Randomized, Placebo-Contolled, Single- and Multiple-Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmocokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Treatment Naive Subjects with Chronic Heptitis B Virus Infection.

Sponsor:  Gilead
Indication: Hepatitis B
Criteria: No previous treatment; requires overnight stays at the CTRI
Phase: 1
Drug: GS-9620 oral small-molecule TLR7-agonist

GS-US-283-0110: A Long-Term Follow-Up Registry Study of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gilead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepatits B Infection

Sponsor:  Gilead
Indication: Hepatitis B
Criteria: Failed GS-6920 treatment
Registry study: No drug involved;Data collection only

FISSION--P7977-1231A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naive Patients with Chronic Genotype 2 or 3 HCV Infection.

Sponsor:  Pharmassett
Indication: Hepatitis C
Criteria: No previous treatment; Genotype 2 or 3
Phase: 3
Drug: PSI-7977 in combination with ribavirin
Drug: Pegylated interferon in combination with ribavirin

P2938-0721—QUANTUM:  An International, Multicenter, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Chronic HCV Infection.

Sponsor:  Pharmassett
Indication: Hepatitis C
Criteria: No previous treatment; All Genotypes; Child-Pugh A Cirrhosis; Liver biopsy within 2 years
Phase: 1
Drug: PSI-352938, PSI-7977, and Ribavirin 

Visit the Clinical Translational Research Institute (CTRI) for more information on clinical research in health sciences.